2Strands Biosciences is an early-stage precision diagnostics company developing blood-based monitoring tests for cancer patients. Its proprietary target enrichment strategy uses specialized probes and biochemical steps to achieve exceptional assay performance, aiming to deliver better, cheaper, and faster testing compared to existing options.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer patients typically require invasive tissue biopsies or imaging scans to monitor their disease status and treatment response. These methods can be costly, slow, and uncomfortable, limiting how frequently clinicians can assess disease progression and adjust therapies in a timely manner.
Solution
2Strands Biosciences develops blood-based monitoring tests that offer a less invasive and more accessible alternative for tracking cancer. The company's innovative target enrichment strategy employs proprietary probes and biochemical steps to isolate and analyze circulating biomarkers with high precision. This approach is designed to deliver exceptional performance while being more cost-effective and faster than conventional diagnostic methods. By enabling simpler sample collection and streamlined workflows, 2Strands aims to support more frequent and convenient monitoring for cancer patients throughout their care journey.
Target Audience
Primary customers are oncologists and clinical care teams managing cancer patients who require regular disease monitoring, as well as diagnostic laboratories and healthcare providers seeking more accessible blood-based testing solutions.
Features
- Proprietary probe-based target enrichment technology for high-sensitivity biomarker capture from blood samples
- Biochemical enrichment steps designed to improve assay specificity and reduce background noise
- Blood-based testing format that eliminates the need for invasive tissue collection procedures
- Focus on cost efficiency and faster turnaround times compared to traditional diagnostic approaches